Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNO in Pulmonary Embolism
NCT04996667Phase 2
Key facts
- Status
- Withdrawn
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- University of California, Los Angeles
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Drugs
- nitric oxide
- Conditions
- pulmonary embolism (PE)
01
Overview
Phase 2, open-label trial of nitric oxide in pulmonary embolism (PE) (2 cohorts), sponsored by University of California, Los Angeles. Primary endpoints: Right Atrial Pressure, Right Ventricular Pressure and 12 more. Planned start Jun 2026; status: withdrawn.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Interventional Radiology Arm (Invasive Cohort)
Patients undergoing catheter-based intervention. Invasive hemodynamic measurements via right heart catheterization.
Non-intervention Arm (Non-invasive Cohort)
Patients not undergoing catheter-based intervention. Non-invasive hemodynamic measurements.
03
Who it enrols
Adult patients hospitalized with imaging-proven acute intermediate/submassive or massive pulmonary embolism requiring ICU level of care.
04
Endpoints
Primary
Right Atrial Pressure
Right Ventricular Pressure
Pulmonary Arterial Pressure
Pulmonary Capillary Wedge Pressure
Cardiac Output
Beyond the preview
Go deeper on NCT04996667.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996667.